You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 142 No. 5, May 2006 TABLE OF CONTENTS
  Archives
  •  Online Features
  Study
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (8)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Radiologic Imaging
 •Hematology/ Hematologic Malignancies
 •Leukemias/ Lymphomas
 •Computed Tomography
 •Neoplasms
 •Alert me on articles by topic

Staging Accuracy in Mycosis Fungoides and Sézary Syndrome Using Integrated Positron Emission Tomography and Computed Tomography

Eunice Y. Tsai, MD; Alan Taur, MD; Leandro Espinosa, MD; Andrew Quon, MD; Denise Johnson, MD; Sarah Dick, MD; Steve Chow, MD; Ranjana Advani, MD; Roger Warnke, MD; Sabine Kohler, MD; Richard T. Hoppe, MD; Youn H. Kim, MD

Arch Dermatol. 2006;142:577-584.

Objectives  To evaluate the usefulness of integrated positron emission tomography and computed tomography (PET/CT) in staging mycosis fungoides (MF) and Sézary syndrome and to correlate PET/CT data with histopathologic diagnosis of lymph nodes (LNs).

Design  A single-center, prospective cohort analysis.

Setting  Academic referral center for cutaneous lymphoma.

Patients  Thirteen patients with MF and SS at risk for secondary LN involvement.

Interventions  Patients were clinically evaluated based on general physical examination, total body skin examination, and laboratory screening. They underwent integrated PET/CT followed by excisional biopsy of LNs.

Main Outcome Measures  We used PET/CT to assess LN size and metabolic activity. Enlarged LNs were defined as axillary or inguinal LNs with a short axis 1.5 cm or larger; or cervical LN, with a short axis 1.0 cm or larger. We classified LN pathologic results according to National Cancer Institute (LN1-4) and World Health Organization (WHO 1-3) criteria. We quantified PET activity using standardized uptake value (SUV) and correlated with LN grade.

Results  Based on CT size criteria alone, only 5 patients had enlarged LNs, whereas PET revealed hypermetabolic LNs in all 13 patients. Six patients had LN1-3, and 7 had effacement of LN architecture by lymphoma cells (LN4). Of the 7 patients with LN4 nodes, 4 had SS, and 3 had tumorous MF. Two patients with LN4 nodes had inguinal LNs smaller than 1.5 cm and would have been assigned an N0 classification without the use of integrated PET/CT. Correlation of SUV with LN grade revealed that LN1-3 nodes were associated with a mean SUV of 2.7 (median SUV, 2.2; range, 2.0-4.7) and LN4 nodes were associated with a mean SUV of 5.4 (median SUV, 3.9; range, 2.1-11.8). Patients with large cell transformation had the highest SUVs.

Conclusions  For staging MF and SS, PET/CT was more sensitive in detecting LN involved by lymphoma compared with CT data alone and thus may provide more accurate staging and prognostic information. The intensity of PET activity correlated with histologic LN grade.


Author Affiliations: Departments of Dermatology (Drs Tsai, Dick, Chow, and Kim), Radiology/Nuclear Medicine (Drs Taur, Espinosa, and Quon), Surgery (Dr Johnson), Oncology (Dr Advani), Pathology (Drs Warnke and Kohler), and Radiation Oncology (Dr Hoppe), Stanford University School of Medicine, Stanford, Calif.



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

FDG-PET in T-cell and NK-cell neoplasms
Kako et al.
Ann Oncol 2007;18:1685-1690.
ABSTRACT | FULL TEXT  

TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC)
Kim et al.
Blood 2007;110:479-484.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.